LOTTE Biologics to Expand CDMO Partnerships at DCAT Week 2026 in New York

Seoul, South Korea – March 9, 2026 – LOTTE Biologics announced its participation in DCAT Week 2026, a prominent global pharmaceutical and biotechnology event taking place in New York City from March 23 to 26. The company aims to explore new partnership opportunities and strengthen its position in the contract development and manufacturing organization (CDMO) sector.

DCAT Week: A Key Industry Gathering

DCAT Week is an annual event that brings together pharmaceutical companies, CDMOs, and other life sciences stakeholders to discuss collaboration opportunities and industry trends. LOTTE Biologics will host a series of meetings at the Lotte New York Palace Hotel, the event’s venue, to engage with potential partners and explore business opportunities, particularly within the North American market.

Leveraging Dual-Site Capabilities

LOTTE Biologics will highlight the synergy between its Syracuse Bio Campus in New York and the Songdo Bio Campus in Incheon, South Korea. The Songdo Bio Campus’s Plant 1 is scheduled for mechanical completion in August 2026. This dual-site model aims to provide global partners with flexible and reliable manufacturing capabilities.

Expanding Service Offerings Through Collaboration

The company is also emphasizing the expansion of its service capabilities through strategic collaborations. Specifically, its ongoing collaboration with Asimov, a U.S.-based cell line development expert, allows LOTTE Biologics to offer conclude-to-end DNA to Drug Substance (DS) services. This collaboration streamlines capabilities, offering timelines of approximately 8.5 months from transfection to drug substance release, supporting various modalities including monoclonal and bispecific antibodies, and providing step-by-step manufacturing options from clinical trials to GMP production.

Looking Ahead

“DCAT Week is an important gathering where key decision-makers across the global pharmaceutical and biotechnology industry arrive together,” said a representative from LOTTE Biologics. Through its participation, LOTTE Biologics intends to actively seek cooperation opportunities with potential customers and further expand its competitiveness in the global market.